0000000000046385

AUTHOR

Giovanni Filocamo

showing 13 related works from this author

IL-1 BLOCKADE IN PAEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY OF THE ITALIAN COHORT

2019

Introduction: Acute pericarditis is an inflammatory condition causing the occurrence of pericardial effusion. In a third of patients, the disease is recurrent. First line treatment of idiopathic pericarditis consists in non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine; glucocorticoids represent the second line treatment in resistant or intolerant cases. A recent clinical trial has enlightened the effectiveness of anakinra in adults and paediatric patients with colchicine-resistant recurrent pericarditis. Objectives: To describe the clinical characteristics and response to treatment in a cohort of paediatric patients with recurrent pericarditis treated with IL inhibitors. Method…

Settore MED/38 - Pediatria Generale E SpecialisticaRecurrent pericarditis Anakinra Colchicine-resistence Canakinumab
researchProduct

Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sec…

2021

Summary Background Presenting symptoms of childhood cancers might mimic those of rheumatic diseases. However, the evidence available to guide differential diagnosis remains scarce. Preventing wrong or delayed diagnosis is therefore important to avoid incorrect administration of glucocorticoid or immunosuppressive therapy and worsening of prognosis. As such, we aimed to assess the prevalence and characteristics of presenting musculoskeletal manifestations in patients at cancer onset and to identify the factors that differentiate childhood malignancies with arthropathy from juvenile idiopathic arthritis. Methods We did a multicentre, cross-sectional study at 25 paediatric haemato-oncology cen…

medicine.medical_specialtybusiness.industryImmunologyArthritisCancerOdds ratioMusculoskeletal manifestationJuvenile idiopathic arthritismedicine.diseaseHistiocytosisRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPrednisoneInternal medicineJoint painArthropathyMusculoskeletal manifestations childhood cancer juvenile idiopathic arthritismedicinechildhood cancerImmunology and AllergyDifferential diagnosismedicine.symptombusinessmedicine.drug
researchProduct

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicent…

2017

Summary Background Little evidence-based information is available to guide the treatment of oligoarticular juvenile idiopathic arthritis. We aimed to investigate whether oral methotrexate increases the efficacy of intra-articular corticosteroid therapy. Methods We did this prospective, open-label, randomised trial at ten hospitals in Italy. Using a concealed computer-generated list, children younger than 18 years with oligoarticular-onset disease were randomly assigned (1:1) to intra-articular corticosteroids alone or in combination with oral methotrexate (15 mg/m 2 ; maximum 20 mg). Corticosteroids used were triamcinolone hexacetonide (shoulder, elbow, wrist, knee, and tibiotalar joints) o…

musculoskeletal diseasesmedicine.medical_specialtyPopulationArthritisInjections Intra-Articular03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicinemedicinemedia_common.cataloged_instanceHumans030212 general & internal medicineProspective StudiesEuropean unionAdverse effecteducationmedia_common030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryMedicine (all)General MedicineMethylprednisolone acetateJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileSurgeryClinical trialMethotrexateTreatment OutcomeItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMethotrexateOligoarticular Juvenile Idiopathic Arthritisbusinessmedicine.drug
researchProduct

ASSESSING THE CLINICAL RELEVANCE AND RISK MINIMIZATION OF ANTIBODIES TO BIOLOGICS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) (ABIRISK) - PRELIMINARY RESU…

2018

Introduction: ABIRISK is a project funded by Innovative Medicine Initiative, with the aim to investigate anti-drug antibody (ADA) formation in the treatment of JIA with biologics (BPs). A major limitation to the use of biologics is the development of ADA that may decrease the efficacy of BPs. Objectives: The aim of this project is to improve the capability to predict biologic immunogenicity in JIA patients. Methods: JIA Patients (by ILAR criteria) followed by 24 PRINTO centres in 12 countries were prospectively enrolled and treated with Etanercept, Adalimumab or Tocilizumab. Patient’s data were obtained from Pharmachild, a pharmacovigilance data registry of JIA patients. For each patient de…

Settore MED/38 - Pediatria Generale E SpecialisticaJIA ABIRISK
researchProduct

A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry

2017

Abstract Background Behçet’s disease is a rare multi-systemic inflammatory disease with unknown etiology which involves principally oral and genital mucosa, skin and eyes. Average age at onset of the disease is about 25-30 years, but it may be diagnosed before the age of 16. It is not very rare in Italy, even though there are limited data concerning epidemiology. Aim of this study is to describe the baseline data of an Italian cohort of patients with as having BD or probable BD. Methods We described the baseline data of the first national epidemiological study on children coming from 16 Italian Pediatric Rheumatologic Centers diagnosed by the treating physicians as having Behçet’s Disease. …

Malelcsh:Diseases of the musculoskeletal systemDiagnostic criteriaCross-sectional studyConstitutional symptomsBehcet's diseasePediatricsCohort StudiesBehçet’s diseaseBiological Factors0302 clinical medicineEpidemiologyImmunology and AllergyLongitudinal StudiesRegistries030212 general & internal medicineBehçet’s disease Children Clinical features Diagnostic criteria Treatment Pediatrics Perinatology and Child Health Rheumatology Immunology and AllergyChildChildrenBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Adolescent; Behcet Syndrome; Biological Factors; Child; Cohort Studies; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Longitudinal Studies; Male; Registries; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergyeducation.field_of_studyBehçet's diseaseBehcet Syndromelcsh:RJ1-570Perinatology and Child HealthItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACohortFemaleImmunosuppressive AgentsResearch ArticleCohort studyBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergymedicine.medical_specialtyAdolescentPopulationBehçet's disease03 medical and health sciencesRheumatologyInternal medicinemedicineHumansBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyeducationGlucocorticoids030203 arthritis & rheumatologybusiness.industrylcsh:PediatricsClinical featuresmedicine.diseaseTreatmentCross-Sectional StudiesClinical featurePediatrics Perinatology and Child HealthEtiologylcsh:RC925-935business
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

2018

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsPatient Reported Outcome MeasurePsychometricsHealth StatusArthritisJuvenilePredictive Value of TestHealth StatuDisability Evaluation0302 clinical medicineMedicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPatientPrognosisDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Adolescent; Age of Onset; Arthritis Juvenile; Case-Control Studies; Child; Child Preschool; Cultural Characteristics; Female; Health Status; Humans; Italy; Male; Parents; Patients; Predictive Value of Tests; Prognosis; Psychometrics; Quality of Life; Reproducibility of Results; Rheumatology; Translating; Disability Evaluation; Patient Reported Outcome MeasuresCultural CharacteristicSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyChild PreschoolPredictive value of testsFemaleCase-Control StudiePsychometricHumanmedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsPrognosiImmunologyReproducibility of ResultDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; Immunology03 medical and health sciencesJuvenile idiopathic arthritiQuality of life (healthcare)RheumatologyDisease status Functional ability Health Related Quality of Life JAMAR Juvenile idiopathic arthritis Adolescent Age of Onset Arthritis Juvenile Case-Control Studies Child Child Preschool Cultural Characteristics Female Health Status Humans Italy Male Parents Patients Predictive Value of Tests Prognosis Psychometrics Quality of Life Reproducibility of Results Rheumatology Translating Disability Evaluation Patient Reported Outcome MeasuresPredictive Value of Tests030225 pediatricsInternal medicineJuvenileHumansValidation StudiesPatient Reported Outcome MeasuresDisease statuPreschool030203 arthritis & rheumatologyCultural Characteristicsbusiness.industryArthritisReproducibility of ResultsHealth Related Quality of LifeTranslatingJuvenile idiopathic arthritismedicine.diseaseFunctional abilityArthritis JuvenileRheumatologyParentCase-Control StudiesQuality of LifeAge of onsetbusiness
researchProduct

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis

2014

In contrast with the numerous controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular JIA. As a result, the management of children with this subtype, which is the most prevalent in Western countries, is largely empiric. Intra-articular corticosteroid (IAC) injection is the therapy of first choice for oligoarthritis in many pediatric rheumatology centers. However, although IAC injections are usually highly efficacious, relapses of synovitis are common and sometimes occur only a few months after the procedure. It is still unclear whether concomitant administration of methotrexate (MTX) may …

musculoskeletal diseasesPediatricsmedicine.medical_specialtyArthritislaw.inventionSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyRandomized controlled triallawInternal medicineSynovitismedicineImmunology and AllergyPediatrics Perinatology and Child Healthskin and connective tissue diseasesmethotrexate oligoarticular juvenile idiopathic arthritisOligoarthritisbusiness.industrymedicine.diseaseRheumatologyConcomitantPoster PresentationPediatrics Perinatology and Child HealthMethotrexateOligoarticular Juvenile Idiopathic Arthritisbusinessmedicine.drugPediatric Rheumatology
researchProduct

Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis

2020

Made available in DSpace on 2021-06-25T10:38:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-11-01 Healthway Objective. To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. Methods. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 wee…

MaleClinical assessment; Composite disease activity score; Disease activity; Outcome measures; Pediatric rheumatology; Still's disease; Systemic juvenile idiopathic arthritismedicine.medical_specialtyFeverClinical assessmentComposite disease activity scoreArthritisLymphadenopathyDiseaseSeverity of Illness IndexOutcome measuresOutcome measureJuvenile Arthritis Disease Activity ScoreRheumatologyCronbach's alphaSystemic juvenile idiopathic arthritisInternal medicineStill's diseaseContent validityMedicineJuvenileHumansPharmacology (medical)Pediatric rheumatologyDisease activityRange of Motion ArticularChildPain MeasurementSerositisThrombocytosisbusiness.industryConstruct validityReproducibility of ResultsAnemiaExanthemamedicine.diseaseArthralgiaRheumatologyArthritis JuvenileChild PreschoolSplenomegalyQuality of LifeFemaleHyperferritinemiabusinessHepatomegaly
researchProduct

Pediatric Recurrent Pericarditis: Appropriateness of the Standard of Care and Response to IL-1 Blockade

2022

Objective: To analyze, in a cohort of pediatric patients with recurrent pericarditis undergoing anti-interleukin (IL)-1 treatment: the agent and dosing used as first-line treatment, the long-term efficacy of IL-1 blockers, the percentage of patients achieving a drug-free remission, and the presence of variables associated with drug-free remission. Study design: Data were collected from patients' charts. The annualized relapse rate (ARR) was used for evaluation of treatment efficacy, and bivariate logistic regression analysis was used for variables associated with drug-free remission. Results: Fifty-eight patients, treated between 2008 and 2018, were included in the study (mean follow-up. 2.…

anti-inflammatory agents nonsteroidal colchicine interleukin-1 pericarditis steroids therapytherapySettore MED/38 - Pediatria Generale E SpecialisticaSettore MED/09 - Medicina Internaanti-inflammatory agents non-steroidal; colchicine; interleukin-1; pericarditis; steroids; therapyanti-inflammatory agents nonsteroidalanti-inflammatory agents non-steroidalPediatrics Perinatology and Child Healthanti-inflammatory agents nonsteroidal; colchicine; interleukin-1; pericarditis; steroids; therapypericarditiscolchicineinterleukin-1steroidsThe Journal of Pediatrics
researchProduct

IL-1 BLOCKADE IN PEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY ON THE ITALIAN COHORT

2019

Background: Acute pericarditis is an inflammatory condition causing the occurrence of pericardial effusion. In a third of patients, the disease is recurrent. Most of the cases are idiopathic or occur after a pericardial procedure. First line treatment of idiopathic pericarditis consists in NSAIDs and colchicine; glucocorticoids represent the second line treatment in resistant or intolerant cases. The use of different biologics and immunosoppressant has been reported, with variable responses. A recent clinical trial has enlightened the effectiveness of anakinra in patients with colchicine-resistant recurrent pericarditis. Objectives: To describe the clinical characteristics and response to t…

Acute pericarditis colchicine anakinraSettore MED/38 - Pediatria Generale E Specialistica
researchProduct